|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 135.26 USD | +3.03% |
|
+0.83% | +6.22% |
| 07-30 | Merck, Wellcome partner with global health group to make Ebola vaccine for clinical trials | RE |
| 07-28 | Atea Pharmaceuticals Says Combination Drug Meets Endpoints in Phase 3 Hepatitis C Trial | MT |
| Market Cap | 163B 142B 132B 121B 229B 15,559B 232B 1,555B 610B 7,746B 612B 599B 25,974B | P/E 2026 * |
-47.3x | P/E 2027 * | 16.6x |
|---|---|---|---|---|---|
| Enterprise Value | 173B 150B 140B 128B 242B 16,476B 246B 1,646B 646B 8,202B 648B 634B 27,504B | EV / Sales 2026 * |
5.67x | EV / Sales 2027 * | 5.05x |
| Free-Float |
99.88% | Yield 2026 * |
2.51% | Yield 2027 * | 2.6% |
Last Transcript: Gilead Sciences, Inc.
| 1 day | -0.69% | ||
| 1 week | +0.83% | ||
| Current month | +3.20% | ||
| 1 month | +3.50% | ||
| 3 months | -0.96% | ||
| 6 months | -8.75% | ||
| Current year | +6.22% |
| 1 week | 128.28 |  | 136.26 |
| 1 month | 126.46 | | 140.61 |
| Current year | 116.88 | | 157.29 |
| 1 year | 108.46 | | 157.29 |
| 3 years | 62.07 | | 157.29 |
| 5 years | 57.16 | | 157.29 |
| 10 years | 56.56 | | 157.29 |
| Manager | Title | Age | Since |
|---|---|---|---|
Daniel O'Day
CEO | Chief Executive Officer | 61 | 28/02/2019 |
Andrew Dickinson
DFI | Director of Finance/CFO | 56 | 31/10/2019 |
Keeley Wettan
CMP | Compliance Officer | - | 17/12/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Kelly Kramer
BRD | Director/Board Member | 58 | 18/08/2016 |
| Director/Board Member | 73 | 31/12/2017 | |
Harish Manwani
BRD | Director/Board Member | 72 | 08/05/2018 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 15/07/26 | Sell | Executive/Senior Manager | -3,000 | 0.0002% | ||
| 15/07/26 | Sell | Chief Financial Officer | -3,000 | 0.0002% | ||
| 01/07/26 | Sell | Chief Executive Officer | -15,000 | 0.0012% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +3.03% | +0.83% | +16.11% | +71.24% | 163B | |
| -0.91% | -3.99% | +55.16% | +152.62% | 1,030B | |
| +0.92% | -2.53% | +55.84% | +53.24% | 617B | |
| -2.85% | -2.81% | +33.36% | +68.52% | 455B | |
| +0.06% | +1.17% | +36.21% | +31.25% | 350B | |
| -0.14% | -0.83% | +33.24% | +40.28% | 299B | |
| -0.69% | -0.44% | +9.86% | +14.23% | 265B | |
| -7.37% | -4.31% | -5.69% | -41.99% | 225B | |
| -0.75% | +2.48% | +30.59% | +64.59% | 209B | |
| +0.82% | +2.14% | +7.62% | -30.49% | 142B | |
| Average | -1.10% | +4.47% | +27.23% | +42.35% | 375.46B | |
| Weighted average by Cap. | -0.95% | +4.73% | +37.40% | +69.05% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 30.42B 26.45B 24.62B 22.6B 42.68B 2,904B 43.34B 290B 114B 1,446B 114B 112B 4,848B | 32.3B 28.08B 26.13B 23.99B 45.31B 3,083B 46.01B 308B 121B 1,535B 121B 119B 5,147B |
| Net income | -3.39B -2.95B -2.74B -2.52B -4.76B -324B -4.83B -32.34B -12.69B -161B -12.73B -12.45B -540B | 9.78B 8.5B 7.91B 7.26B 13.72B 934B 13.93B 93.27B 36.61B 465B 36.73B 35.92B 1,558B |
| Net Debt | 9.6B 8.34B 7.77B 7.13B 13.46B 916B 13.67B 91.54B 35.93B 456B 36.04B 35.25B 1,529B | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 31/07/26 | US$130.41 | -0.66% | 4,518,767 |
| 30/07/26 | US$131.28 | -1.09% | 6,726,143 |
| 29/07/26 | US$132.73 | -1.18% | 7,766,370 |
| 28/07/26 | US$134.32 | +2.91% | 6,947,167 |
| 27/07/26 | US$130.52 | +0.94% | 4,953,801 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- GILD Stock
Select your edition
All financial news and data tailored to specific country editions
